e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The potential impact of azithromycin in idiopathic pulmonary fibrosis
Claudio Macaluso, Joaquín Maritano Furcada, Omamah Alzaher, Ritesh Chaube, Felix Chua, Athol U. Wells, Toby M. Maher, Peter M. George, Elizabeth A. Renzoni, Philip L. Molyneaux
Source:
Eur Respir J, 53 (2) 1800628; 10.1183/13993003.00628-2018
Journal Issue:
February
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Claudio Macaluso, Joaquín Maritano Furcada, Omamah Alzaher, Ritesh Chaube, Felix Chua, Athol U. Wells, Toby M. Maher, Peter M. George, Elizabeth A. Renzoni, Philip L. Molyneaux. The potential impact of azithromycin in idiopathic pulmonary fibrosis. Eur Respir J, 53 (2) 1800628; 10.1183/13993003.00628-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation
Source: Eur Respir J 2012; 40: 794-795
Year: 2012
Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J, 50 (4) 1701157; 10.1183/13993003.01157-2017
Year: 2017
The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis
Source: ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021
Year: 2021
Pirfenidone in idiopathic pulmonary fibrosis
Source: Eur Respir J 2010; 35: 821-829
Year: 2010
Pirfenidone in idiopathic pulmonary fibrosis
Source: Eur Respir J 2010; 36: 695-696
Year: 2010
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
Source: Eur Respir J 2016; 48: 843-851
Year: 2016
The changing treatment landscape in idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2015; 24: 65-68
Year: 2015
Antifibrotic choice in idiopathic pulmonary fibrosis
Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF)
Year: 2018
Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Year: 2019
A comparison of pirfenidone versus nintedanib for the management of idiopathic pulmonary fibrosis
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Source: Eur Respir J 2015; 45: 1434-1445
Year: 2015
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
Source: Eur Respir Rev 2012; 21: 161-167
Year: 2012
The clinical relevance of autoimmunity in idiopathic pulmonary fibrosis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease II
Year: 2012
The impact of emphysema in pulmonary fibrosis
Source: Eur Respir Rev 2013; 22: 153-157
Year: 2013
Effects of short-term pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 628s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept